Bachem is celebrating its fifty-year anniversary this year. The company was founded in 1971 by the entrepreneur Peter Grogg.
Over the course of half a century, the company has become a global player in the development and production of peptides, important ingredients for a range of medicines that treat cancer, diabetes and other diseases.
In 1977, Bachem moved with eight employees to Bubendorf, where the company remains headquartered today.
The company now employs more than 1,500 people at six locations worldwide. Last year, it generated over $437m for the first time and hired 272 employees. The company hopes to grow further in the coming years and plans to invest more than $430m in expansion throughout the next five years.
The anniversary celebrations for employees, originally planned on site, will be held as a virtual event due to the COVID-19 pandemic.
Peter Grogg, founder said: "Today we celebrate 50 exciting and successful years of company history. Bachem's success continues to be rooted in the skills and dedication of its employees. I am certain that Bachem has many more exciting and successful years ahead of it."
Kuno Sommer, Chairman of the Board of Directors said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."
Thomas Meier, CEO said: "Today's anniversary is a commitment to the next 50 years. We intend and are able to continue to grow independently and profitably. That is why we are continuing to invest in the future of all our sites. In doing so, we will build on our strengths: our company culture and our commitment to high quality, innovation and customer focus."
